insights_auto
Why is ENOV down 2.90%?
Dive Deeperchevron_right
ENOV:NYSE
Enovis Corp
$25.47
arrow_downward
-2.90%(-0.76) 1D
$25.47
0.00% (0.00)
bedtimeAfter hours
Closed: Nov 20, 4:00:04 PM GMT-5 · USD
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ENOV...
Open
$26.16
High
$26.62
Low
$25.38
Mkt. cap
1.47B
Avg. vol.
1.62M
Volume
1.22M
52-wk high
$31.66
52-wk low
$16.70
EPS
-$9.22
Beta
1.08
Shares outstanding
57.70M
No. of employees
8K
Open
$26.16
High
$26.62
Low
$25.38
Mkt. cap
1.47B
Avg. vol.
1.62M
Volume
1.22M
52-wk high
$31.66
52-wk low
$16.70
EPS
-$9.22
Beta
1.08
Shares outstanding
57.70M
No. of employees
8K
News stories
From web sources and news partners
ChartMill
·
1 hour ago
S&P 500 Top Movers: Today's Biggest Gainers and Losers
FXStreet
·
12 minutes ago
Dow Jones Industrial Average drops for a fifth day as AI rout widens
WHEC.com
·
10 minutes ago
S&P 500 sinks 3.7% and the Nasdaq composite goes negative for the year as rout in tech stocks tanks the market
finance.biggo.com
·
21 minutes ago
Goldman Sachs: Year-End S&P 500 Rally Could Lose Half Its Punch as Fear Runs Hot
Profile
Enovis Corporation is a medical technology company with a focus in orthopedics. The company was founded by brothers Mitchell and Steven Rales as the Colfax Corporation in 1995. Enovis is headquartered in Dallas, Texas and is listed on the NYSE as ENOV. The company has over 8,000 employees operating at 30 sites around the world. Wikipedia
About Enovis Corp
CEOMatthew L. Trerotola
Employees7.8K
Founded1995
HeadquartersWilmington, Delaware, United States
SectorHealth Care
IndustryMedical device
Websiteenovis.com
Analyst ratings
Based on 9 analysts giving stock ratings to ENOV in the past 3 months
Strong buy
Buy
8
Hold
1
Sell
0
12-month forecast
Based on 9 Wall Street analysts offering 12 month price targets for ENOV in the last 3 months.
Highest
Current $25.47
$47.00 (+84.53%)
Average
$37.78 (+48.33%)
Lowest
$27.00 (+6.01%)
Analyst | Recommendation | Action | Price target | Projected | Date |
|---|---|---|---|---|---|
Robbie Marcus J.P. Morgan | Hold | Maintained | $27.00 | +6% | 11/09/2026 |
Vik Chopra BMO Capital | Buy | Maintained | $31.00 | +21.7% | 11/06/2026 |
Caitlin Cronin Canaccord Genuity | Buy | Reiterated | $42.00 | +64.9% | 11/06/2026 |
Caitlin Roberts Canaccord Genuity | Buy | Reiterated | $42.00 | +64.9% | 11/06/2026 |
Larry Biegelsen Wells Fargo | Buy | Reiterated | $37.00 | +45.3% | 11/06/2026 |
Ryan Zimmerman BTIG | Buy | Maintained | $42.00 | +64.9% | 11/05/2026 |
Michael Matson Needham | Buy | Maintained | $34.00 | +33.5% | 10/12/2026 |
Patrick Wood UBS | Buy | Maintained | $44.00 | +72.8% | 10/05/2026 |
David Turkaly Citizens JMP | Buy | Maintained | $47.00 | +84.5% | 09/02/2026 |
Keith Hinton Freedom Capital Markets | Buy | Maintained | $36.00 | +41.3% | 09/01/2026 |
Steven Lichtman William Blair | Buy | Maintained | - | - | 08/14/2026 |
Vijay Kumar Evercore ISI | Buy | Maintained | $32.00 | +25.6% | 08/07/2026 |
Rong Li Jefferies | Buy | Reiterated | $40.00 | +57% | 07/14/2026 |
Unknown Analyst Jefferies | Buy | Reiterated | $40.00 | +57% | 07/14/2026 |
Unknown Analyst BMO Capital | Buy | Initiated | $29.00 | +13.9% | 07/09/2026 |
Jeff Johnson Robert W. Baird | Buy | Maintained | $37.00 | +45.3% | 05/08/2026 |
Last report
Nov 5, 2026
Fiscal period
Q3 2026
- Normalized EPS / Est. (USD)
- GAAP EPS / Est. (USD)
$0.88 / $0.77
+14.76%beat
arrow_upward
Revenue / Est. (USD)
558.72M / 557.15M
+0.28%beat
arrow_upward
Fiscal Q3 2026 earnings call
youtube_liveWaiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in USD | Dec 2025 | Apr 2026 | Jul 2026 | Oct 2026 |
|---|---|---|---|---|
Revenue | 575.76M | 589.15M | 582.78M | 558.72M |
Cost of goods sold | 222.69M | 223.67M | 223.53M | 223.58M |
Cost of revenue | 222.69M | 223.67M | 223.53M | 223.58M |
Research and development expenses | 31.36M | 31.53M | 31.69M | 31.28M |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 249.84M | 270.58M | 261.61M | 242.88M |
Operating expense | 326.38M | 344.02M | 334.86M | 317.40M |
Total operating expenses | 549.08M | 567.69M | 558.39M | 540.98M |
Operating income | 26.68M | 21.46M | 24.39M | 17.74M |
Other non operating income | 1.93M | 3.27M | -1.91M | 3.78M |
EBT including unusual items | -509.55M | 634.00K | 7.46M | -456.00K |
EBT excluding unusual items | 21.10M | 15.57M | 14.44M | 13.91M |
Income tax expense | 9.26M | 9.04M | 8.50M | -1.68M |
Effective tax rate | -1.82% | 1,426.66% | 113.88% | 368.20% |
Other operating expenses | - | - | - | - |
Net income | -520.59M | -8.76M | -1.19M | 3.14M |
Net profit margin | -90.42% | -1.49% | -0.20% | 0.56% |
Earnings per share | 0.95 | 0.89 | 0.90 | 0.88 |
Interest and investment income | 12.60M | 10.00M | 10.50M | 8.70M |
Interest expense | -20.11M | -19.17M | -18.54M | -16.32M |
Net interest expenses | -7.51M | -9.17M | -8.04M | -7.62M |
Depreciation and amortization charges | - | - | - | - |
EBITDA | 103.69M | 94.82M | 95.42M | 91.25M |
Gain or loss from assets sale | 329.00K | -75.00K | 843.00K | 192.00K |
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider | Position | Type | Date | Shares | Amount |
|---|---|---|---|---|---|
Page 1
Upcoming events